Temporal trends in in-hospital complications of acute coronary syndromes: Insights from the nationwide AMIS Plus registry.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 08 2020
Historique:
received: 08 12 2019
revised: 29 03 2020
accepted: 01 04 2020
pubmed: 20 4 2020
medline: 15 5 2021
entrez: 20 4 2020
Statut: ppublish

Résumé

Acute coronary syndrome (ACS)-related morbidity and mortality remain substantial. Data on temporal trends in in-hospital complications of ACS patients are scarce. This study sought to investigate whether the incidence of in-hospital complications of ACS patients changed over time. Acute coronary syndrome patients prospectively enrolled in the National Registry of Acute Myocardial Infarction in Switzerland (AMIS Plus) between 2003 and 2018 and with available data on in-hospital complications were included in the analysis. Rates of in-hospital complications, including recurrent angina, recurrent myocardial infarction, cerebrovascular events, cardiogenic shock, bleeding, acute renal failure, sepsis/systemic inflammatory response syndrome (SIRS)/multiorgan dysfunction syndrome (MODS), AV block needing pacing and new-onset atrial fibrillation, were assessed for each 2-year period. Among 47,845 ACS patients, in-hospital complications significantly decreased from 22.0% in 2003/2004 to 18.9% in 2017/2018 (p for trend <0.001). An initial decline in rates of in-hospital complications to 15.7% in 2009/2010 (p for trend <0.001) was followed by a constant increase thereafter (p for trend = 0.002). While rates of recurrent angina, recurrent myocardial infarction, and cardiogenic shock decreased over time, rates of bleeding events, acute renal failure, sepsis/SIRS/MODS, and new-onset atrial fibrillation increased. Rates of in-hospital complications were higher in women, mainly due to a constantly increased risk of bleeding and AV block needing pacing. The decrease in ischemic complications was paralleled by a concomitant increase in non-ischemic events. These findings emphasize that advanced strategies targeting non-ischemic complications are warranted to further improve quality of care of ACS patients.

Sections du résumé

BACKGROUND
Acute coronary syndrome (ACS)-related morbidity and mortality remain substantial. Data on temporal trends in in-hospital complications of ACS patients are scarce. This study sought to investigate whether the incidence of in-hospital complications of ACS patients changed over time.
METHODS
Acute coronary syndrome patients prospectively enrolled in the National Registry of Acute Myocardial Infarction in Switzerland (AMIS Plus) between 2003 and 2018 and with available data on in-hospital complications were included in the analysis. Rates of in-hospital complications, including recurrent angina, recurrent myocardial infarction, cerebrovascular events, cardiogenic shock, bleeding, acute renal failure, sepsis/systemic inflammatory response syndrome (SIRS)/multiorgan dysfunction syndrome (MODS), AV block needing pacing and new-onset atrial fibrillation, were assessed for each 2-year period.
RESULTS
Among 47,845 ACS patients, in-hospital complications significantly decreased from 22.0% in 2003/2004 to 18.9% in 2017/2018 (p for trend <0.001). An initial decline in rates of in-hospital complications to 15.7% in 2009/2010 (p for trend <0.001) was followed by a constant increase thereafter (p for trend = 0.002). While rates of recurrent angina, recurrent myocardial infarction, and cardiogenic shock decreased over time, rates of bleeding events, acute renal failure, sepsis/SIRS/MODS, and new-onset atrial fibrillation increased. Rates of in-hospital complications were higher in women, mainly due to a constantly increased risk of bleeding and AV block needing pacing.
CONCLUSIONS
The decrease in ischemic complications was paralleled by a concomitant increase in non-ischemic events. These findings emphasize that advanced strategies targeting non-ischemic complications are warranted to further improve quality of care of ACS patients.

Identifiants

pubmed: 32305559
pii: S0167-5273(19)36050-4
doi: 10.1016/j.ijcard.2020.04.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

16-24

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The AMIS Plus registry is funded by unrestricted grants from the Swiss Heart Foundation and from Abbott Medical AG, Amgen AG, AstraZeneca AG, Bayer AG, Biotronik (all Switzerland) AG, Boston Scientific AG, B. Braun Medical AG, Cordis-Cardinal Health GmbH, Daiichi Sankyo (Switzerland) AG, Medtronic (Switzerland) AG, Novartis Pharma Switzerland AG, Sanofi-Aventis (Switzerland) SA, Servier (Switzerland) SA, SIS Medical Distribution AG, Terumo Germany GmbH, Vascular Medical GmbH, Swiss Working Group for Interventional Cardiology. The sponsors did not play any role in the design, data collection, analysis, or interpretation of the registry.

Auteurs

Barbara E Stähli (BE)

Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland. Electronic address: barbara.staehli@usz.ch.

Marco Roffi (M)

Division of Cardiology, University Hospital Geneva, Geneva, Switzerland.

Franz R Eberli (FR)

Division of Cardiology, Triemli Hospital, Zurich, Switzerland.

Hans Rickli (H)

Department of Cardiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.

Paul Erne (P)

AMIS Plus Data Center, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland.

Marco Maggiorini (M)

Medical Intensive Care Unit, Institute of Intensive Care Medicine, University Hospital Zurich, Switzerland.

Giovanni Pedrazzini (G)

Department of Cardiology, Cardiocentro Ticino, Lugano, Switzerland.

Dragana Radovanovic (D)

AMIS Plus Data Center, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH